DiaSorin S.p.A.

Company Overview

DiaSorin S.p.A. is a global leader in the laboratory diagnostics market, focusing on the immunodiagnostics and molecular diagnostics segments. The company acquired Luminex in July 2021, which is involved in developing products and services related to molecular diagnostics and research.

Luminex provides molecular diagnostic products and services categorized as infectious diseases, genetics, diagnostic reagents, instruments, and technological solutions. Some of Luminex’s well-established instruments and technologies are Luminex 100/200, ARIES and ARIES M1 Systems, VERIGENE System, MAGPIX System, VERIGENE II System xTAG Technology, xMAP Technology, VERIGENE NanoGrid technology and MultiCode-RTx Technology. In July 2021, DiaSorin S.p.A. completed the acquisition of Luminex Corp.

• Luminex Corp. subsidiary, Nanosphere Inc., manufactures products for molecular biology and molecular diagnostics for disease detection for gastroenteric, respiratory and bloodstream infections. The company developed a technology platform, the Verigene System, which detects complex and deadly infectious diseases through a multiplexed diagnostic test.

• Tm Bioscience part of Luminex Corp. developed a series of Tag-It tests and Analyte Specific Reagents for many genetic disorders. These tests are based on Tag-It Universal Array platform. The genetic detection assays developed by Tm Bioscience for cystic fibrosis are FDA cleared for diagnostic purposes in the U.S. Luminex offers these as companion diagnostics kits for cystic fibrosis. The company’s main offerings in this area are xTAG Cystic Fibrosis 60 Kit v2, xTAG Data Analysis Software (TDAS) CFTR, xTAG Cystic Fibrosis 39 Kit v2 and xTAG CYP2D6 Kit v3.

Financial Highlights (FY 2023)

Company's Business Segments

• In-Vitro Diagnostics Reagent : The company developes, manufactures, and markets in vitro diagnostics reagent kits and systems.